Aktürk Esen, SelinErgün, YakupErol, CihanArıkan, RukiyeEr, Muhammed Muhiddin2022-11-082022-11-082022Esen, S. A., Ergun, Y., Erol, C., Arikan, R., Er, M. M., Atci, M. M., . . . Uncu, D. (2022). First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer. Bosnian Journal of Basic Medical Sciences, 22(5), 818-825. doi:10.17305/bjbms.2021.7069https://doi.org/10.17305/bjbms.2021.7069https://hdl.handle.net/20.500.12713/3261Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which plati-num-based treatment should be preferred. This study aimed to compare the treatment response and survival characteristics of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer who received f luorouracil, oxaliplatin, and leucovo-rin (mFOLFOX)+trastuzumab or cisplatin and f luorouracil (CF)+trastuzumab as first-line therapy. It was a multicenter, retrospective study of the Turkish Oncology Group, which included 243 patients from 21 oncology centers. There were 113 patients in the mFOLF-OX+trastuzumab arm and 130 patients in the CF+trastuzumab arm. The median age was 62 years in the mFOLFOX+trastuzumab arm and 61 years in the CF+trastuzumab arm (p = 0.495). About 81.4% of patients in the mFOLFOX+trastuzumab arm and 83.1% in the CF+trastuzumab arm had gastric tumor localization (p = 0.735). The median progression-free survival (PFS) was significantly higher in the mFOLFOX+trastuzumab arm (9.4 months vs. 7.3 months, p = 0.024). The median overall survival (OS) was similar in both groups (18.4 months vs. 15.1 months, p = 0.640). Maintenance trastuzumab was continued after chemotherapy in 101 patients. In this subgroup, the median OS was 23.3 months and the median PFS was 13.3 months. In conclusion, mFOLFOX+trastuzumab is similar to CF+trastuzumab in terms of the median OS, but it is more effective in terms of the median PFS in the first-line treatment of HER2-positive metastatic gastric and GEJ cancer. The choice of treatment should be made by considering the prominent toxicity findings of the chemotherapy regimens.eninfo:eu-repo/semantics/openAccessCFFOLFOXGastric CancerGastroesophageal Junction CancerTrastuzumabArticle225818825WOS:0008834586000052-s2.0-85138273094Q310.17305/bjbms.2021.7069N/A